46 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp00480 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Epithelial cancer | CC50 : 26.5 ± 2.4 μM |
| dbacp00481 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Chronic myeloid Leukemia | CC50 : 26.5 ± 2.4 μM |
| dbacp00482 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Gastric cancer | CC50 : 26.5 ± 2.4 μM |
| dbacp00483 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Breast cancer | CC50 : 26.5 ± 2.4 μM |
| dbacp00484 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | CRL-1739 | Cervical cancer | CC50 : 26.5 ± 2.4 μM |
| dbacp00485 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Epithelial cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00486 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Chronic myeloid Leukemia | CC50 : 2.0 ± 0.1 μM |
| dbacp00487 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Gastric cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00488 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Breast cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00489 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MM96L | Cervical cancer | CC50 : 2.0 ± 0.1 μM |
| dbacp00490 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Epithelial cancer | CC50 : 14.7 ± 1.5 μM |
| dbacp00491 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Chronic myeloid Leukemia | CC50 : 14.7 ± 1.5 μM |
| dbacp00492 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Gastric cancer | CC50 : 14.7 ± 1.5 μM |
| dbacp00493 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Breast cancer | CC50 : 14.7 ± 1.5 μM |
| dbacp00494 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HFF-1 | Cervical cancer | CC50 : 14.7 ± 1.5 μM |
| dbacp00495 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Epithelial cancer | CC50 : 20.9 ± 1.4 μM |
| dbacp00496 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Chronic myeloid Leukemia | CC50 : 20.9 ± 1.4 μM |
| dbacp00497 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Gastric cancer | CC50 : 20.9 ± 1.4 μM |
| dbacp00498 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Breast cancer | CC50 : 20.9 ± 1.4 μM |
| dbacp00499 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HeLa | Cervical cancer | CC50 : 20.9 ± 1.4 μM |
| dbacp00500 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Epithelial cancer | CC50 : 15.2 ± 1.9 μM |
| dbacp00501 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Chronic myeloid Leukemia | CC50 : 15.2 ± 1.9 μM |
| dbacp00502 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Gastric cancer | CC50 : 15.2 ± 1.9 μM |
| dbacp00503 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Breast cancer | CC50 : 15.2 ± 1.9 μM |
| dbacp00504 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | MCF-7 | Cervical cancer | CC50 : 15.2 ± 1.9 μM |
| dbacp00505 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Epithelial cancer | CC50 : 1.3 ± 0.1 μM |
| dbacp00506 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Chronic myeloid Leukemia | CC50 : 1.3 ± 0.1 μM |
| dbacp00507 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Gastric cancer | CC50 : 1.3 ± 0.1 μM |
| dbacp00508 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Breast cancer | CC50 : 1.3 ± 0.1 μM |
| dbacp00509 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | K-562 | Cervical cancer | CC50 : 1.3 ± 0.1 μM |
| dbacp00510 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Epithelial cancer | CC50 : 15.7 ±1.1μM |
| dbacp00511 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Chronic myeloid Leukemia | CC50 : 15.7 ±1.1μM |
| dbacp00512 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Gastric cancer | CC50 : 15.7 ±1.1μM |
| dbacp00513 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Breast cancer | CC50 : 15.7 ±1.1μM |
| dbacp00514 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | HL-60 | Cervical cancer | CC50 : 15.7 ±1.1μM |
| dbacp00515 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Epithelial cancer | CC50 : 10.4 ± 1.0 μM |
| dbacp00516 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Chronic myeloid Leukemia | CC50 : 10.4 ± 1.0 μM |
| dbacp00517 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Gastric cancer | CC50 : 10.4 ± 1.0 μM |
| dbacp00518 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Breast cancer | CC50 : 10.4 ± 1.0 μM |
| dbacp00519 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic construct | Target and destroy tumor cell membranes | Cell viability assay | PBMCs | Cervical cancer | CC50 : 10.4 ± 1.0 μM |
| dbacp06809 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | CRL-1739 | Gastric Cancer | CC50 = 26.5 ± 2.4 μM |
| dbacp06810 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MM96L | Skin Cancer | CC50 = 2.0 ± 0.1 μM |
| dbacp06811 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | HeLa | Cervical Cancer | CC50 = 20.9 ± 1.4 μM |
| dbacp06812 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | MCF-7 | Breast Cancer | CC50 = 15.2 ± 1.9 μM |
| dbacp06813 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | K-562 | Leukemia Cancer | CC50 = 1.3 ± 0.1 μM |
| dbacp06814 | [G1K, L5Y, K8R]cGm | KCRRYCYRQRCVTYCRGR | Synthetic Analogue of Gomesin | Cell membrane penetration | Resazurin dye assay | HL-60 | Leukemia Cancer | CC50 = 15.7 ±1.1μM |